Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 18c

Go back to Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 18c

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

February 8, 2022 4:05 PM EST

Fourth Quarter 2021 Revenue of $24.2 Million and Full Year 2021 Revenue of $96.1 Million

Launch of QINLOCK® in Europe Underway

Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Data Expected in 2H 2022

Phase 1 Single Agent Dose Escalation Data for DCC-3116 Expected in 2H 2022; Initiation of Phase 1 Combination Dose Escalation Cohorts Expected in 2H 2022

New Development Candidate from Pan-RAF Research Program Expected in 2022

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced... More